Company news from the 05/05/06 News Brief

Share this article:
Biovail and AstraZeneca have entered into an agreement in which Biovail’s specialty sales force will promote AstraZeneca’s Zoladex (goserelin acetate implant) to obstetricians and gynecologists for the treatment of endometriosis in the US and Puerto Rico. Financial terms of the deal were not disclosed. AstraZeneca will continue to manufacture and supply all quantities of Zoladex, according to a joint statement from the companies. Biovail’s 85-member specialty sales force currently promotes Zovirax Cream and Zovirax Ointment, topical anti-viral treatments for genital herpes and cold sores, to specialists and selected primary-care physicians in the US.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions